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Abstract
Objective: Despite progress in treating relapsing multiple sclerosis (MS), effec-
tive inhibition of nonrelapsing progressive MS is an urgent, unmet, clinical
need. Animal models of MS, such as experimental autoimmune
encephalomyelitis (EAE), provide valuable tools to examine the mechanisms
contributing to disease and may be important for developing rational therapeu-
tic approaches for treatment of progressive MS. It has been suggested that mye-
lin oligodendrocyte glycoprotein (MOG) peptide residues 35-55 (MOG35-55)-
induced EAE in nonobese diabetic (NOD) mice resembles secondary progres-
sive MS. The objective was to determine whether the published data merits
such claims. Methods: Induction and monitoring of EAE in NOD mice and lit-
erature review. Results: It is evident that the NOD mouse model lacks validity
as a progressive MS model as the individual course seems to be an asyn-
chronous, relapsing-remitting neurodegenerative disease, characterized by
increasingly poor recovery from relapse. The seemingly progressive course seen
in group means of clinical score is an artifact of data handling and interpreta-
tion. Interpretation: Although MOG35-55-induced EAE in NOD mice may pro-
vide some clues about approaches to block neurodegeneration associated with
the inflammatory penumbra as lesions form, it should not be used to justify tri-
als in people with nonactive, progressive MS. This adds further support to the
view that drug studies in animals should universally adopt transparent raw data
deposition as part of the publication process, such that claims can adequately
be interrogated. This transparency is important if animal-based science if it is
to remain a credible part of translational research in MS.
Introduction
Multiple sclerosis (MS) is an immune-mediated, demyeli-
nating disease of the central nervous system (CNS).1 This
typically follows a relapsing-remitting disease course often
followed by the accumulation of progressively worsening
neurological disability.1 Active neurological disease in MS 2
and disease in the experimental autoimmune
encephalomyelitis (EAE) model of MS is driven by the
consequences of the peripheral, adaptive immune
response entering the CNS.56 This is supported not only
by radiological and pathological findings, but most
importantly, by the response to therapy.4–7 Although pro-
gressive MS may also respond to similar immunotherapy
provided there is sufficient neurological reserve in the
nerve-tracks affected,8–10 other factors such as innate
immune responses are thought to be of central impor-
tance in progressive neurodegeneration.11 This concept
underpins the perceived treatment-failure of immunother-
apy in advanced (progressive) MS, where replacement of
peripheral immunity, which stops relapses, does not
always halt accumulation of disability.8,9,12,13 Therefore,
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
1
there is an urgent need for model systems that can be used
to identify the pathological mechanism operating in
progressive disease as well as to design and test new
therapeutics.
Experimental autoimmune encephalomyelitis in ani-
mals is a group of experimentally induced autoimmune
diseases with some similarities to MS.14,15 Some of the
EAE models are associated with the development of
relapsing, immune-mediated demyelination disease14,16
and may show slow accumulation of disability that is
independent of relapses and peripheral autoimmunity.17–20
The nonobese diabetic (NOD) mouse develops sponta-
neous or induced diabetes and other endocrine gland-
associated autoimmunities.21–23 This mouse strain has
also been reported to develop progressive neurological
disease that mimics progressive MS.24,25 Progressive
worsening appears to develop within 20–30 days postin-
duction following immunization with myelin oligoden-
drocyte glycoprotein (MOG) peptide residues 35-55
(MOG35-55).24–31 Thus, this EAE model could have sig-
nificant utility for screening potential neuroprotective
and repair agents.24,27–31 Here, we have investigated the
response of NOD mice to various autoantigens to assess
the validity of this system to model progressive MS. In
contrast to some of the published literature indicating
the progressive nature of early MOG35-55 induced EAE
in NOD mice, we found no evidence that this model
exhibits a progressive worsening independent of relaps-
ing disease indicating that existing data are an artifact of
data handling and interpretation. Therefore, this model
should not be used to justify any human trials in nonre-
lapsing progressive MS.
Methods
Animals
NOD/Lt (NOD), NOD.H2Ea (NOD-E) mice expressing
a transgenic H-2A alpha chain allowing expression of
H-2Eg7 and NOD.H2AbAsp (NOD-ASP) mice expressing
a modified H-2A beta with a serine to aspartic acid
substitution at position 57 were from stock bred at the
University of Cambridge.22 These mice failed to
develop diabetes during the course of these studies.
Animals were housed and used according to the Ani-
mals (Scientific Procedures) Act 1986, which induces
review by the local Animal Welfare and Ethical Review
Body and the United Kingdom Government, Home
Office Inspectorate. In addition, NOD/ShiLtJ mice were
from stock bred at the La Trobe University.32 Animal
procedures were approved by the Institutional Animal
Care and Use Committee at the La Trobe Institute,
Australia.23,32
Experimental autoimmune
encephalomyelitis
Animals (11–15 week) were injected subcutaneously with
1 mg mouse spinal cord homogenate (SCH),16 200lg
mouse proteolipid protein residues 56-70 (PLP56-70) pep-
tide33,34 or 200 lg MOG residues 8-22 (MOG8-22) pep-
tide34,35 emulsified in Freunds adjuvant supplemented
with 60 lg Mycobacteria tuberculosis and M.butyricum on
day 0 and 7.16 Animals were injected intraperitoneally
with 200 ng Bordetella pertussis toxin immediately and
24 h after each injection of antigen, as described previ-
ously.16,32,33 These are the immunodominant myelin pep-
tides associated with H-2Ag7 reactivity in ABH mice.33–35
Animals were scored as 0 = normal; 1 = limp tail;
2 = impaired righting reflex; 3 = hindlimb paresis;
4 = hindlimb paralysis; 5 = moribund (endpoint) as
described previously.16,33 Alternatively, animals (9–
12 week) were immunized with 200 lg MOG residues
35-55 (MOG35-55) peptide emulsified in Freunds complete
adjuvant supplemented with 4 mg/mL M. tuberculosis on
day 0 and 350 ng intravenous B.pertussis toxin on day 0
and day 2.23,32 These mice were scored as: 0 = no signs,
1 = limp tail, 2 = hindlimb weakness, 3 = hindlimb
weakness with at least one paralyzed hindlimb, 4 = paral-
ysis of both hindlimbs and weakness of one forelimb,
5 = moribund.23 Animals were randomly assigned to
treatments and the studies were scored blinded to induc-
tion agent. Groups contained a minimum of five animals/
group which was sufficient to perform statistical analysis
and experimental elements relevant to the ARRIVE guide-
lines have been reported previously.13,15 Raw data sup-
plied as Data S1.
Statistical analysis
Data were analyzed using Sigmplot (Systat Software Inc,
London) and expressed as mean  standard error of the
mean. For EAE group clinical scores and day of disease
onset were assessed by Mann–Whitney U tests. Group
EAE score represents the maximal neurological deficit in
all animals within the group and mean EAE score the
maximal neurological deficit developed by mice that ex-
hibited EAE, as previously described.33,36 P values < 0.05
were considered significant.
Results
Biozzi ABH mice (H2dq1: Kd, Ag7, E-, Dq) are susceptible
to a number of induced autoimmunities37 exhibit high-
susceptibility to SCH-induced EAE compared to NOD
(H2 g7:Kd, Ag7,E-, Db) mice, which share the diabetogenic
H-2Ag7 molecule.37,38 However, NOD mice can show
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comparable susceptibility to other induced autoimmuni-
ties when B.pertussis toxin is used as coadjuvant.39 The
immunodominant epitopes associated with the develop-
ment of EAE in ABH mice are proteolipid protein
(PLP56-70) and myelin oligodendrocyte glycoprotein
(MOG8-22) peptides.33,34 However, wild-type NOD
mice only exhibited modest susceptibility (n = 9/13) to
SCH-induced EAE (Fig 1; Table 1), with disease that had
poor consistency in severity (Range of maximum severity
Grade 0.5–4 n = 9) and day of onset (range 14–49.
n = 9). Of those mice that developed disease 6/9 devel-
oped relapses by day 63 and none showed a slow progres-
sive worsening of disease. Similarly, MOG8-22 peptide
induced disease in 13/14 mice, which largely relapsed
(n = 9/13), and again no escalating progressive disease
was evident. Interestingly, it was found that wild-type
mice poorly responded to PLP56-70 peptide and only 5/13
(38.5%) mice developed low-grade EAE (Table 1). Like-
wise, NOD.ASP mice developed low-grade EAE (Fig. 1).
However, NOD-E mice exhibited significantly (P < 0.001)
more severe disease than wild-type mice immunized with
PLP56-70, as described previously.40 This was evident when
the group score (2.1  0.3 vs. 0.5  0.2; P < 0.001) and
the EAE score (2.3  0.3 vs. 1.2  0.2; P < 0.05) were
analyzed (Table 1). Although some NOD-E mice re-
lapsed, there was no evidence of progressive worsening.
Previous studies have examined the encephalitogenic
response to MOG35-55 in NOD mice.24,41 This is a sub-
dominant MOG peptide in both the ABH (H-2 g7) and
C57BL/6 (H-2b) mice.34,42 This peptide tends to induce a
monophasic chronic EAE in ABH and C57BL/6 mice,
where there is poor recovery following a single attack.42–
44 This is consistent with the neurodegenerative nature of
the attacks.45 Therefore, the effect of MOG35-55 peptide
was not assessed in the initial studies (Fig. 1). An appar-
ent progressive worsening of neurological signs can be
observed when analyzing the group means of ABH ani-
mals with SCH-induced EAE,16 yet it is clear that in indi-
vidual mice the course of disease is relapsing-remitting
that responds to T-cell immunotherapy.16,17,46 The appar-
ent continuing worsening of disease is simply due to the
occurrence of asynchronous relapses with increasingly
poor recovery due to the neurodegenerative effects of the
inflammatory penumbra.16,19,20,46 This may explain the
disease course reported in NOD mice.24–31
Therefore, to avoid unnecessary use of animals, the lit-
erature was investigated further. Indeed, the first descrip-
tions of MOG35-55 reported that the disease in NOD mice
was relapsing and remitting.23,41,47 Importantly, when the
data from individual animals are examined it is clear that
disease was largely relapsing and remitting and not pro-
gressive48 and was confirmed here using available data
(Fig. 2). Thus the apparent progressive worsening was
largely due to asynchronous relapses with poor recovery
(Fig. 2). The relapsing nature of EAE in NOD mice was
reproducibly supported by the results from different labo-
ratories.23,47–49 Indeed, the literature (Fig. 3) indicates
that defining MOG-induced EAE in NOD mice as pro-
gressive, is a misinterpretation and misrepresentation of
what actually is a neurodegenerative, relapsing disease
profile.26,45
Discussion
This study demonstrates that MOG-induced EAE in NOD
mice induces a relapsing disease course that is not reflec-
tive of chronic, progressive MS in its early phases. This is
consistent with the original description of MOG35-55-in-
duced disease in NOD/Lt mice as being a relapsing-remit-
ting disease.41 However, when mice were followed for up
to several months longer it was reported that disease
might become chronically progressive as animals accumu-
late disability.47 However, with the urgent unmet clinical
need to develop treatment options for advanced MS,
MOG35-55 induced EAE has become used as a “progres-
sive EAE” model that purportedly resembles secondary
progressive MS.24,25,48 This clinical progression appears to
begin from about day 20 after immunization when it is
used to test therapeutics for use in progressive MS.24–31
However, through literature review and as shown here,
the same clinical course has been reported to be a form
of chronic relapsing EAE.23,48–50 At the cellular level, CD4
T cells from MOG35-55 T-cell receptor (TCRMOG)-specific
transgenic NOD mice, that select CD4 and CD8 T cells,
induce a phenotypic progressive disease in NOD.Scid
mice, similar to that reported using MOG35-55 immunized
wild-type NOD mice.51 However, based on the disease
occurring following active immunization in NOD.
TCRMOG mice, it is clearly evident that a relapsing-remit-
ting course developed.51 Indeed, the initial disease was
described to be of mild severity that completely resolved
followed by relapse of greater severity that did not resolve
completely.51 Histologically, every attack is associated
with the development of severe immune-infiltration52 and
thus lacks evidence of progression without significant
blood–brain barrier dysfunction similar to progressive
MS.53 Importantly, the pathology demonstrates that these
immune attacks cause significant neurodegeneration, con-
sistent with EAE in other mouse strains including C57BL/
6 mice,16,36,45 leading to persistent disability that often
increases with each cycle of neurological attack. Thus the
concept of progressive worsening in the clinical score of
NOD mice, is a misrepresentation of what is clearly an
asynchronous-neurodegenerative, relapsing EAE.
Such relapses, driven by T cells17,51 will of course
respond to immunotherapy. This could limit the
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Figure 1. Induction of EAE in NOD mice using myelin peptides. EAE was induced by subcutaneous injection of neuroantigen in Freunds adjuvant
and using B.pertusssis toxin as coadjuvant. The results represent the group mean daily  SEM.
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generation of neurodegeneration by prevention of lesion
formation or by inhibiting the consequence of the inflam-
matory penumbra that is associated with the formation of
lesions in the central nervous system.20,45,54 Indeed,
MOG35-55 induced NOD mouse EAE responds to prophy-
lactic and therapeutic T-cell tolerance induction and T-
cell immunotherapy.26,27 However, that these approaches
have largely failed to markedly influence nonactive, pro-
gressive MS, demonstrates that the model as used, proba-
bly has no or limited validity and predictive value for
efficacy in nonactive, progressive MS.12,13,55,56 Therefore,
the model should not be used to justify any clinical trials
in nonrelapsing, progressive MS.2
Any agent that diminishes the frequency of attacks and
reduces their severity will be potentially secondarily neu-
roprotective, as seen in both EAE and MS.3,57 In addition,
the inflammatory penumbra occurring during active EAE
and MS is damaging and can cause nerve loss.45,54,58,59 As
such, it is sometimes difficult to dissociate direct neuro-
protective effects against the inflammatory penumbra
from secondary neuroprotection due to immunomodula-
tion that prevents lesion formation. This is particularly
the case when treating during active paralytic disease and
monitoring recovery,3,54,60 such as that occurring in
monophasic, neurodegenerative MOG-induced EAE in
C57BL/6 mice.43,61 Although one can show that agents
are not immunosuppressive in vitro, drugs that interfere
with nervous system signaling can cause adverse effects
in vivo, although these are seldom reported in animal
studies.3,60,62 Such drugs that interfere with neuronal sig-
naling could induce a stress response that could be
immunosuppressive. Thus, it is imperative that these
influences are avoided if insight into neuroprotection is
required.3,60,62 This is because, while immunomodulation
of the adaptive immune response may be of benefit for
active progressive MS3,8–10 it cannot adequately inform
about effects operating in nonactive progressive MS.2
Until this aspect is appreciated by experimental biologists
and clinicians, we will fail to adequately model
progressive MS and continue to fail to translate ideas into
human benefit.
Although not reported here, our previous studies have
reported the histological profile of EAE in NOD mice.22
This is consistent with other mouse strains that demon-
strate a dynamic degree of adaptive immune cells infiltra-
tion as clinical disease develops and wanes.22,36 Glial cell
inflammation is thought to be part of the substrate for
slow progressive nerve loss in MS.11 However, the loss of
axons and myelin, accumulation of microglial activation
and gliosis reported in progressive EAE models,24–31 is
not qualitatively different from that found following the
accumulation of disability from relapsing EAE in
mice.20,36 This perhaps is not surprising as monophasic
or relapsing inflammatory disease activity probably creates
and conditions the neurodegenerative environment that
leads to the slow loss nerve loss, which does not respond
rapidly to agents that target relapsing disease.17–20 Pro-
gressive neurodegenerative pathology, driven by glial cells,
initially coexists with adaptive immune inflammation
driving active attacks, but becomes more dominant with
disease duration as relapses wain, as occurs in NOD mice
with long disease duration.22,47
Given the deficits that NOD mice accumulate due to
relapsing attacks, it is likely that slow progressive disease
eventually develops, as a similar disease course is
observed in SCH-induced EAE in ABH.17,18,23 Following
accumulation of deficit from relapsing attacks, animals
exhibit slow clinical worsening and nerve loss, weeks to
months after disease induction, which is not responsive
to peripheral immunosuppression.17–20 Although this
degenerative process is occurring following initial
attacks,20 this becomes notably evident during the
postattack period that occurs following monophasic EAE
that occurs in MOG35-55-induced EAE in C57BL/6,43,44
chronic relapsing EAE in ABH17,18 and possibly NOD
mice.23,47 It is possible that subtle differences in the
genetics of the animals, age, sex, microbiome content,
and breeding facility could account for the differences in
Table 1. Disease susceptibility of transgenic nonobese diabetic mice to myelin antigens
Strain Immunogen No. EAE Group Score EAE Score Day of Onset
NOD SCH 9/13 2.0  0.5 2.8  0.5 27.1  14.9
NOD MOG8-22 13/14 1.5  0.3 1.7  0.3 17.3  6.4
NOD PLP56-70 5/13 0.5  0.2 1.2  0.2 20.6  9.3
NOD-E PLP56-70 11/12** 2.1  0.3*** 2.3  0.3* 21.6  4.7
NOD MOG35-55 14/14 2.3  0.1# 2.3  0.1# 13.2  3.1
EAE was induced by subcutaneous injection of neuroantigen in Freunds adjuvant and using B. pertusssis toxin as coadjuvant. The results represent
the mean maximum group score of the first episode  SEM; the mean maximum score of animals that developed EAE during the first episode 
SEM and the mean day of onset  SD. The NOD mice immunized with SCH, MOG8-22 or PLP56-70 were from stock based in the United Kingdom.
The NOD mice immunized with MOG35-55 peptide were from different stock based in Australia and #the scoring system used was different.
*P < 0.05; **P < 0.01, ***P < 0.001 compared to wild-type mice.
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Figure 2. Individual disease courses in NOD mice. NOD mice were immunized with 200 lg MOG35-55 and 4 mg/mL complete Freunds adjuvant.
The results represent the group mean  SEM neurological score (n = 14) and the individual scores over time.
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Figure 3. Progressive worsening of EAE disease in NOD mice is a misrepresentation of relapsing-remitting EAE. NOD mice were immunized with
150 lg MOG35-55 and 4 mg/mL complete Freunds adjuvant in the progressive EAE model. (A) The results demonstrating a progressive worsening
was shown using a mean daily group score  SEM. These mice were treated (arrow) with MOG35-55 nasal tolerance or bovine serum albumin
(BSA) peptide as control. Differences between the groups are shown. *P < 0.05 assessed using a Student’s t test. While a t test is not appropriate
for such nonparametric data,3,68 the lack of consistent statistical differences demonstrates the fluctuating nature of the individual data points that
form the group score. (B) As each mouse had a relapse and remission at different time points, the average clinical score of each relapse and
remission was calculated, clearly showing disease is relapsing remitting.26 Figures are reproduced from Levy Barazany H et al. Exp Neurol 2014;
255:63-7026; doi.org/10.1016/j.expneurol.2014.02.010 with permission from Elsevier.
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the clinical profile reported here and as shown previ-
ously by us23 and that reported by others.24–31 Indeed,
in some of our studies, male and older mice tolerate
inflammatory insults less well and accumulate nerve loss
and deficits leading to the slow accumulation of progres-
sive disability, even following a single attack.54,63,64 In
our experience this deficit accumulates slowly17,18 and
was reported to occurs in NOD mice months, not weeks
after disease development.23,47 Age and sex, however, are
unlikely to account for differences in the clinical course
observed here, as they were comparable23 to those
reported for rapidly evolving secondary progressive
EAE.23–26 In our experience, this progressive worsening
is not readily captured by the typical subjective, nonlin-
ear, scoring of paralysis of the hindlimbs and tail often
used to assess the severity of EAE in animals.16,23,43,47 As
such, neurological disease eventually plateaus in mouse
EAE and remains stable over months.18,23,43,46,47 This
may change very slowly just as observed in
humans.8,17,65 However, other objective outputs such as
spasticity and mobility changes can detect slow, worsen-
ing over time.17,18 Similarly, although cuprizone-induced
demyelination and subsequent neurodegeneration was
widely assumed to be nonclinical, through analysis of
alternative objective outcome measures clinical deteriora-
tion can be detected.64,66 Therefore, it may be possible
that existing models, if used wisely, such as avoiding
treatment during the periods of active attacks, could be
used to identify candidate agents that may be of value
in controlling nonrelapsing progressive MS. Alternatively
models that mirror aspects of progressive MS can be
developed to facilitate a mechanism-based targeting of
neurodegenerative disease in MS.
The process of the refinement, reduction, and replace-
ment of animal use in research, which defines the ethical
use of animals in research, means that animal experi-
ments should have value in uncovering human biology
and we should particularly strive to limit the number of
animals used in severe procedures. EAE is such a severe
procedure and thus should not be used if less-severe sys-
tems, or shorter disease durations, can address the same
central hypothesis. We have already seen that there has
been poor translation of animal studies into the treatment
of relapsing MS.67 It is important that we do better in
finding treatments for progressive MS. The definition of
EAE in NOD mice as a progressive model appears to be
based on the trajectory of the mean disease scores, but it
is clear from this study that this description is a misrepre-
sentation of the disease course of individual mice. We
have made the case previously that it is essential that
more information such as maximum and minimum score
and number of animals with disease be presented such
that graphs of group disease scores can be better
interpreted.3,68 This, however, ultimately requires access
to the raw data.
Access to the source data is being requested of clinical
trials (www.clinicalstudydatarequest.com) to limit data
hacking and hiding.4,69 Although some journals are
requesting statements that data are accessible, in the elec-
tronic age there is now no barrier to depositing raw data
in workable spreadsheets. This is because a statement of
supply of raw data can be hollow and unenforced. With
deposition of raw data during submission of manuscripts
such data can be interrogated by the reviewers and the
readers. This would thus make the preclinical space more
responsive and reproducible, as poor quality data are less
likely to be submitted or published and can more quickly
be challenged, avoiding the need to replicate studies.3,15,68
This is important as there is sometimes a lack of quality
control in EAE studies where the data from control groups
may be highly inconsistent and appears to sometimes fluc-
tuate depending on whether an experimental-treatment
aims to find an augmentation or inhibition of disease.70,71
This, coupled with poor-reporting, notably of bias reduc-
tion, and data handling that can influence outcomes can
lead to overinterpretation of data that is probably of mar-
ginal biological significance.3,62,67,72,73 Experimental data
lacking quality control are not likely to be reproducible
between laboratories, let alone between other strains/spe-
cies and importantly have translational value for human
studies.3 There have been many translational failures and
only two of the 15 licensed treatments for MS had their
origins in preclinical MS studies, although the majority of
the other licensed treatments have subsequently been
found to reduced EAE severity.15,67,73 It is therefore
important that preclinical studies are used in a way to
reflect the clinical indication, if they are to have transla-
tional value.3,15,73 Given the drive to perform more
humane animal studies, notably to limit severe procedures
in animals, there is no place for science that causes unnec-
essary animal suffering. Learned societies and governments
need to lead journals to universally adopt transparent data
deposition if animal-based translational neuroscience is to
remain a credible part of research.
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